Myriad Genetics buy DerAlmanach100000
Start price
05.06.25
/
100%
€4.44
Target price
05.06.28
-
Performance (%)
8.56%
End price
06.08.25
€4.82
Summary
This prediction ended on 06.08.25 with a price of €4.82. The BUY prediction by DerAlmanach100000 finished with a performance of 8.56%. DerAlmanach100000 has a follow-up prediction for Myriad Genetics where he still thinks Myriad Genetics is a Buy. DerAlmanach100000 has 100% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Myriad Genetics | 1.467% | 1.467% | -47.811% |
| iShares Core DAX® | 0.184% | 5.072% | 8.979% |
| iShares Nasdaq 100 | -0.770% | -2.079% | 26.437% |
| iShares Nikkei 225® | 0.733% | -3.346% | 47.887% |
| iShares S&P 500 | -0.166% | 0.904% | 22.974% |
According to DerAlmanach100000 what are the pros and cons of Myriad Genetics for the foreseeable future?
Pros
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Very Future proof/growth oriented business model
Market Leader or Top 3
Cons
Comments by DerAlmanach100000 for this prediction
In the thread Trading Myriad Genetics
Current prediction by DerAlmanach100000 for Myriad Genetics
Myriad Genetics
Start price
Target price
Perf. (%)
€6.30
23.11.25
23.11.25
-
23.11.28
23.11.28
-56.68%
08:31
08:31
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Stopped prediction by DerAlmanach100000 for Myriad Genetics
Myriad Genetics
Start price
Target price
Perf. (%)
€4.34
03.06.25
03.06.25
-
03.07.25
03.07.25
8.29%
04.06.25
04.06.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued
Myriad Genetics
Start price
Target price
Perf. (%)
€3.60
17.05.25
17.05.25
-
17.05.28
17.05.28
6.67%
28.05.25
28.05.25
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
Undervalued